Emerging approaches for targeting metabolic vulnerabilities in malignant glioma

Current Neurology and Neuroscience Reports

Volumn 16, Issue 2, 2016, Pages

  Clark, Peter M ^a   Mai, Wilson X ^a   Cloughesy, Timothy F ^a   Nathanson, David A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glioblastoma; Glioma; Glycolysis; Metabolism; Molecular imaging; Targeted therapy

Indexed keywords

DICHLOROACETIC ACID; N [2 CYCLOHEXYLAMINO 1 (2 METHYLPHENYL) 2 OXOETHYL] N (3 FLUOROPHENYL) 2 METHYL 1H IMIDAZOLE 1 ACETAMIDE;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CITRIC ACID CYCLE; DRUG SAFETY; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; LIPOGENESIS; METABOLIC REGULATION; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL TRANSDUCTION; BRAIN; GLIOMA; PATHOLOGY;

BRAIN; GLIOMA; HUMANS; SIGNAL TRANSDUCTION;

EID: 84973494141     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-015-0613-6     Document Type: Article

References (94)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra0708126.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. doi:10.1056/NEJMoa043330.
3. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–8. doi:10.1038/nature07385.
4. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–77. doi:10.1016/j.cell.2013.09.034.
5. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro-oncology. 2015;17(8):1051–63. doi:10.1093/neuonc/nov031.
6. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012;2(5):458–71. doi:10.1158/2159-8290.CD-11-0284.
7. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, et al. De-repression of PDGFRbeta transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013;3(5):534–47. doi:10.1158/2159-8290.CD-12-0502.
8. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014;343(6166):72–6. doi:10.1126/science.1241328.
9. Hamanaka RB, Chandel NS. Targeting glucose metabolism for cancer therapy. J Exp Med. 2012;209(2):211–5. doi:10.1084/jem.20120162.
10. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427–33. doi:10.1016/j.tibs.2010.05.003.
11. Jelluma N, Yang X, Stokoe D, Evan GI, Dansen TB, Haas-Kogan DA. Glucose withdrawal induces oxidative stress followed by apoptosis in glioblastoma cells but not in normal human astrocytes. Mol Cancer Res MCR. 2006;4(5):319–30. doi:10.1158/1541-7786.MCR-05-0061.
12. Graham NA, Tahmasian M, Kohli B, Komisopoulou E, Zhu M, Vivanco I, et al. Glucose deprivation activates a metabolic and signaling amplification loop leading to cell death. Mol Syst Biol. 2012;8:589. doi:10.1038/msb.2012.20.
13. Kennedy CR, Tilkens SB, Guan H, Garner JA, Or PM, Chan AM. Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions. Cancer Lett. 2013;336(2): 299–306. doi:10.1016/j.canlet.2013.03.020.
14. Fack F, Espedal H, Keunen O, Golebiewska A, Obad N, Harter PN, et al. Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas. Acta Neuropathol. 2015;129(1):115–31. doi:10.1007/s00401-014-1352-5.
15. Oudard S, Arvelo F, Miccoli L, Apiou F, Dutrillaux AM, Poisson M, et al. High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer. 1996;74(6):839–45.
16. Chinnaiyan P, Kensicki E, Bloom G, Prabhu A, Sarcar B, Kahali S, et al. The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res. 2012;72(22):5878–88. doi:10.1158/0008-5472.CAN-12-1572-T.
17. Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci. 2013;16(10):1373–82. doi:10.1038/nn.3510.
18. Wieman HL, Wofford JA, Rathmell JC. Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking. Mol Biol Cell. 2007;18(4): 1437–46. doi:10.1091/mbc.E06-07-0593.
19. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988–1004. doi:10.1038/nrd1902.
20. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev. 2001;15(11):1406–18. doi:10.1101/gad.889901.
21. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, et al. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011;208(2):313–26. doi:10.1084/jem.20101470.
22. Deprez J, Vertommen D, Alessi DR, Hue L, Rider MH. Phosphorylation and activation of heart 6-phosphofructo-2-kinase by protein kinase B and other protein kinases of the insulin signaling cascades. J Biol Chem. 1997;272(28):17269–75.
23. Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 2014;4(4):423–33. doi:10.1158/2159-8290.CD-13-0440.
24. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501. doi:10.1038/nrc839.
25. Carriere A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P, et al. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol. 2008;18(17):1269–77. doi:10.1016/j.cub.2008.07.078.
26. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3): 177–85. doi:10.1016/j.cmet.2006.02.002.
27. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013;18(5):726–39. doi:10.1016/j.cmet.2013.09.013.
28. Kefas B, Comeau L, Erdle N, Montgomery E, Amos S, Purow B. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro- Oncology. 2010;12(11):1102–12. doi:10.1093/neuonc/noq080.
29. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452(7184):230–3. URL:http://www.nature.com/ nature/journal/v452/n7184/suppinfo/nature06734_S1.html.
30. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008;452(7184):181–6. URL:http://www.nature.com/nature/ journal/v452/n7184/suppinfo/nature06667_S1.html.
31. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal. 2009;2(97): ra73. doi:10.1126/scisignal.2000431.
32. Ye J, Mancuso A, Tong X, Ward PS, Fan J, Rabinowitz JD, et al. Pyruvate kinase M2 promotes de novo serine synthesis to sustain mTORC1 activity and cell proliferation. Proc Natl Acad Sci USA. 2012;109(18):6904–9. doi:10.1073/pnas.1204176109.
33. Lunt SY, Muralidhar V, Hosios AM, Israelsen WJ, Gui DY, Newhouse L, et al. Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation. Mol Cell. 2015;57(1):95–107. doi:10.1016/j.molcel.2014.10.027.
34. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science. 2011;334(6060):1278–83. doi:10.1126/science.1211485.
35. Kung C, Hixon J, Choe S, Marks K, Gross S, Murphy E, et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem Biol. 2012;19(9):1187–98. doi:10.1016/j.chembiol.2012.07.021.
36. Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol. 2003;206(Pt 12):2049–57.
37. Tsao TS, Burcelin R, Charron MJ. Regulation of hexokinase II gene expression by glucose flux in skeletal muscle. J Biol Chem. 1996;271(25):14959–63.
38. Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24(2):213–28. doi:10.1016/j.ccr.2013.06.014.
39. Xu Y, Liu X-H, Saunders M, Pearce S, Foulks JM, Parnell KM, et al. Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2). Bioorg Med Chem Lett. 2014;24(2):515–9. doi:10.1016/j.bmcl.2013.12.028.
40. Parnell KM, Foulks JM, Nix RN, Clifford A, Bullough J, Luo B, et al. Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol Cancer Ther. 2013;12(8):1453–60. doi:10.1158/1535-7163.MCT-13-0026.
41. Guo C, Linton A, Jalaie M, Kephart S, Ornelas M, Pairish M, et al. Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1, 2-a]pyrimidin-4-ones as novel PKM2 activators. Bioorg Med Chem Lett. 2013;23(11):3358–63. doi:10.1016/j.bmcl.2013.03.090.
42. Boxer MB, Jiang J-K, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, et al. Evaluation of substituted N, N′- diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. J Med Chem. 2010;53(3):1048–55. doi: 10.1021/jm901577g.
43. Walsh MJ, Brimacombe KR, Veith H, Bougie JM, Daniel T, Leister W, et al. 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett. 2011;21(21):6322–7. doi:10.1016/j.bmcl.2011.08.114.
44. J-k J, Boxer MB, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, et al. Evaluation of thieno[3,2-b]pyrrole[3,2- d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett. 2010;20(11):3387–93. doi:10.1016/j.bmcl.2010.04.015.
45. Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012;8(10):839–47. doi:10.1038/nchembio.1060.
46. Bluemlein K, Grüning N-M, Feichtinger RG, Lehrach H, Kofler B, Ralser M. No evidence for a shift in pyruvate kinase PKM1 to PKM2 expression during tumorigenesis. 2011
47. Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009;27(7):1082–6. doi:10.1200/jco.2008.19.1098.
48. Champ CE, Palmer JD, Volek JS, Werner-Wasik M, Andrews DW, Evans JJ, et al. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. J Neuro-Oncol. 2014;117(1):125–31. doi:10.1007/s11060-014-1362-0.
49. Rieger J, Bahr O, Maurer GD, Hattingen E, Franz K, Brucker D, et al. ERGO: a pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 2014;44(6):1843–52. doi:10.3892/ijo.2014.2382.
50. Stafford P, Abdelwahab MG, do Kim Y, Preul MC, Rho JM, Scheck AC. The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond). 2010;7:74. doi:10.1186/1743-7075-7-74.
51. Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, et al. The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS One. 2012;7(5), e36197. doi:10.1371/journal.pone.0036197.
52. Maurer GD, Brucker DP, Bähr O, Harter PN, Hattingen E, Walenta S, et al. Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapy. BMC Cancer. 2011;11:315. doi:10.1186/1471-2407-11-315.
53. Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012;15(6):827–37. doi:10.1016/j.cmet.2012.05.001.
54. Cheng T, Sudderth J, Yang C, Mullen AR, Jin ES, Matés JM, et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc Natl Acad Sci. 2011;108(21):8674–9. doi:10.1073/pnas.1016627108.
55. Maher EA, Marin-Valencia I, Bachoo RM, Mashimo T, Raisanen J, Hatanpaa KJ, et al. Metabolism of [U-13 C]glucose in human brain tumors in vivo. NMR Biomed. 2012;25(11):1234–44. doi:10.1002/nbm.2794.
56. Mergenthaler P, Lindauer U, Dienel GA, Meisel A. Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci. 2013;36(10):587–97. doi:10.1016/j.tins.2013.07.001.
57. Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, et al. Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 2014;159(7):1603–14. doi:10.1016/j.cell.2014.11.025.
58. Janiszewska M, Suva ML, Riggi N, Houtkooper RH, Auwerx J, Clement-Schatlo V, et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012;26(17):1926–44. doi:10.1101/gad.188292.112.
59. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12. doi:10.1126/science.1164382.
60. Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PloS One. 2011;6(5), e19868. doi:10.1371/journal.pone.0019868.
61. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2- hydroxyglutarate. Nature. 2010;465(7300):966. doi:10.1038/nature09132.
62. Birner P, Pusch S, Christov C, Mihaylova S, Toumangelova-Uzeir K, Natchev S, et al. Mutant IDH1 inhibits PI3K/Akt signaling in human glioma. Cancer. 2014;120(16):2440–7. doi:10.1002/cncr.28732.
63. Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, et al. 2- Hydroxyglutarate inhibits ATP synthase and mTOR signaling. Cell Metab. 2015;22(3):508–15. doi:10.1016/j.cmet.2015.06.009.
64. Chesnelong C, Chaumeil MM, Blough MD, Al-Najjar M, Stechishin OD, Chan JA, et al. Lactate dehydrogenase a silencing in IDH mutant gliomas. Neuro-oncology. 2014;16(5):686–95. doi: 10.1093/neuonc/not243.
65. Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, et al. IDH1 mutation induces reprogramming of pyruvate metabolism. Cancer Res. 2015;75(15):2999–3009. doi: 10.1158/0008-5472.CAN-15-0840.
66. Ohka F, Ito M, Ranjit M, Senga T, Motomura A, Motomura K, et al. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. Tumour Biol J Int Soc Oncodev BiolMed. 2014;35(6):5911–20. doi:10.1007/s13277-014-1784-5.
67. Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim S-H, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17–30. doi:10.1016/j.ccr.2010.12.014.
68. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Gliomaderived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science. 2009;324(5924):261–5. doi: 10.1126/science.1170944.
69. Koivunen P, Lee S, Duncan CG, Lopez G, Lu G, Ramkissoon S, et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature. 2012;483(7390):484–8. doi: 10.1038/nature10898.
70. Michelakis ED, Sutendra G, Dromparis P, Webster L, Haromy A, Niven E, et al. Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med. 2010;2(31):31ra4. doi:10.1126/scitranslmed.3000677.
71. Garon E, Christofk H, Hosmer W, Britten C, Bahng A, Crabtree M, et al. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2014;140(3):443–52. doi:10.1007/s00432-014-1583-9.
72. Davis M, Pragani R, Popovici-Muller J, Gross S, Thorne N, Salituro F, et al. ML309: a potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells. Probe Reports from the NIH Molecular Libraries Program. Bethesda (MD); 2010.
73. Zheng B, Yao Y, Liu Z, Deng L, Anglin JL, Jiang H, et al. Crystallographic investigation and selective inhibition of mutant isocitrate dehydrogenase. ACS Med Chem Lett. 2013;4(6):542–6. doi:10.1021/ml400036z.
74. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science. 2013;340(6132): 626–30. doi:10.1126/science.1236062.
75. Deng G, Shen J, Yin M, McManus J, Mathieu M, Gee P, et al. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J Biol Chem. 2015;290(2):762–74. doi:10.1074/jbc.M114.608497.
76. Wu F, Jiang H, Zheng B, Kogiso M, Yao Y, Zhou C, et al. Inhibition of cancer-associated mutant isocitrate dehydrogenases by 2- thiohydantoin compounds. J Med Chem. 2015;58(17):6899–908. doi:10.1021/acs.jmedchem.5b00684.
77. Molenaar RJ, Botman D, Smits MA, Hira VV, van Lith SA, Stap J, et al. Radioprotection of IDH1-mutated cancer cells by the IDH1- mutant inhibitor AGI-5198. Cancer Res. 2015. doi:10.1158/0008-5472.CAN-14-3603.PubMed.
78. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, et al. The AMPK agonist AICAR inhibits the growth of EGFRvIIIexpressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A. 2009;106(31):12932–7. doi:10.1073/pnas.0906606106.
79. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, et al. EGFR signaling through an Akt-SREBP-1-dependent, rapamycinresistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal. 2009;2(101):82. doi:10.1126/scisignal.2000446.
80. Williams KJ, Argus JP, Zhu Y, Wilks MQ, Marbois BN, York AG, et al. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. Cancer Res. 2013;73(9): 2850–62. doi:10.1158/0008-5472.CAN-13-0382-T.
81. Phelps ME. Positron emission tomography provides molecular imaging of biological processes. Proc Natl Acad Sci U S America. 2000;97(16):9226–33.
82. Spence AM, Muzi M, Mankoff DA, O’Sullivan SF, Link JM, Lewellen TK, et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal graymatter. J Nucl Med. 2004;45(10):1653–9.
83. Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. 18FFDOPA kinetics in brain tumors. J Nucl Med Off Publ Soc Nucl Med. 2007;48(10):1651–61. doi:10.2967/jnumed.106.039321.
84. Grassi I, Nanni C, Allegri V, Morigi JJ, Montini GC, Castellucci P, et al. The clinical use of PET with (11)C-acetate. Am J Nucl Med Mol Imaging. 2012;2(1):33–47.
85. Lieberman BP, Ploessl K, Wang L, Qu W, Zha Z, Wise DR, et al. PET imaging of glutaminolysis in tumors by 18F-(2S,4R)4- fluoroglutamine. J Nucl Med Off Publ Soc Nucl Med. 2011;52(12):1947–55. doi:10.2967/jnumed.111.093815.
86. Venneti S, Dunphy MP, Zhang H, Pitter KL, Zanzonico P, Campos C, et al. Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. Science Transl Med. 2015;7(274):274ra17. doi:10.1126/scitranslmed.aaa1009.
87. Horska A, Barker PB. Imaging of brain tumors: MR spectroscopy and metabolic imaging. Neuroimaging Clin N Am. 2010;20(3): 293–310. doi:10.1016/j.nic.2010.04.003.
88. Kwock L, Smith JK, Castillo M, Ewend MG, Collichio F, Morris DE, et al. Clinical role of proton magnetic resonance spectroscopy in oncology: brain, breast, and prostate cancer. Lancet Oncol. 2006;7(10):859–68. doi:10.1016/S1470-2045(06)70905-6.
89. Kalinina J, Carroll A, Wang L, Yu Q, Mancheno DE, Wu S, et al. Detection of Boncometabolite^ 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma. J Mol Med (Berl). 2012;90(10):1161–71. doi:10.1007/s00109-012-0888-x.
90. Choi C, Ganji SK, DeBerardinis RJ, Hatanpaa KJ, Rakheja D, Kovacs Z, et al. 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med. 2012;18(4):624–9. doi:10.1038/nm.2682.
91. Andronesi OC, Kim GS, Gerstner E, Batchelor T, Tzika AA, Fantin VR, et al. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012;4(116):116ra4. doi: 10.1126/scitranslmed.3002693.
92. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, et al. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neuro-Oncol. 2012;107(1):197–205. doi:10.1007/s11060-011-0737-8.
93. Elkhaled A, Jalbert LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gl iomas. Sci Trans l Med. 2012;4(116ra5):116. doi:10.1126/scitranslmed.3002796.
94. Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al. Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell. 2013;23(3):302–15. doi:10.1016/j.ccr.2013.02.003.